Telescope Innovations Presents Results of Third Fiscal Quarter 2025
Telescope Innovations (OTCQB:TELIF), a developer of advanced technologies for pharmaceutical and chemical industries, reported its Q3 2025 financial results. The company achieved revenues of CAD $1.39 million, up from CAD $1.22 million in Q3 2024, with an adjusted EBITA loss of CAD $99,466.
The quarter saw strong performance of their DirectInject-LC™ product, with doubled opportunities compared to Q3 2024 and successful expansion into Asian markets. Telescope is finalizing a Phase 1 Self-Driving Lab platform with Pfizer and has shipped its first battery-grade lithium sulfide samples to major battery industry groups, leveraging its proprietary low-temperature production process.
The company maintains strategic partnerships with Mettler Toledo, Pfizer, and Standard Lithium, positioning itself for continued growth in analytical and automation innovations.Telescope Innovations (OTCQB:TELIF), sviluppatore di tecnologie avanzate per le industrie farmaceutiche e chimiche, ha comunicato i risultati finanziari del terzo trimestre 2025. L'azienda ha registrato ricavi per 1,39 milioni di CAD, in aumento rispetto agli 1,22 milioni di CAD del terzo trimestre 2024, con una perdita EBITA rettificata di 99.466 CAD.
Il trimestre ha evidenziato un’ottima performance del loro prodotto DirectInject-LC™, con opportunità raddoppiate rispetto al Q3 2024 e una riuscita espansione nei mercati asiatici. Telescope sta completando una piattaforma di laboratorio autonomo di Fase 1 con Pfizer e ha spedito i primi campioni di solfuro di litio di qualità per batterie ai principali gruppi dell’industria delle batterie, sfruttando il proprio processo produttivo a bassa temperatura.
L’azienda mantiene partnership strategiche con Mettler Toledo, Pfizer e Standard Lithium, posizionandosi per una crescita continua nelle innovazioni analitiche e di automazione.
Telescope Innovations (OTCQB:TELIF), desarrollador de tecnologías avanzadas para las industrias farmacéutica y química, informó sus resultados financieros del tercer trimestre de 2025. La compañía alcanzó ingresos de 1,39 millones de CAD, frente a 1,22 millones de CAD en el tercer trimestre de 2024, con una pérdida ajustada de EBITA de 99.466 CAD.
El trimestre mostró un sólido desempeño de su producto DirectInject-LC™, con oportunidades duplicadas respecto al Q3 2024 y una exitosa expansión en los mercados asiáticos. Telescope está finalizando una plataforma de laboratorio autónomo de Fase 1 con Pfizer y ha enviado sus primeras muestras de sulfuro de litio de calidad para baterías a importantes grupos de la industria de baterías, aprovechando su proceso de producción a baja temperatura patentado.
La empresa mantiene alianzas estratégicas con Mettler Toledo, Pfizer y Standard Lithium, posicionándose para un crecimiento continuo en innovaciones analíticas y de automatización.
Telescope Innovations (OTCQB:TELIF)는 제약 및 화학 산업을 위한 첨단 기술 개발업체로서 2025년 3분기 재무실적을 발표했습니다. 회사는 1.39백만 캐나다 달러(CAD)의 매출을 기록했으며, 이는 2024년 3분기의 1.22백만 CAD에서 증가한 수치이고, 조정된 EBITA 손실은 99,466 CAD였습니다.
이번 분기에는 DirectInject-LC™ 제품이 강력한 성과를 보였으며, 2024년 3분기 대비 기회가 두 배로 증가했고 아시아 시장으로의 성공적인 확장도 이루어졌습니다. Telescope는 Pfizer와 함께 1단계 자율 실험실 플랫폼을 마무리 중이며, 독자적인 저온 생산 공정을 활용해 주요 배터리 산업 그룹에 배터리 등급 리튬 황화물 샘플을 처음으로 출하했습니다.
회사는 Mettler Toledo, Pfizer, Standard Lithium과 전략적 파트너십을 유지하며 분석 및 자동화 혁신 분야에서 지속적인 성장을 도모하고 있습니다.
Telescope Innovations (OTCQB:TELIF), développeur de technologies avancées pour les industries pharmaceutiques et chimiques, a publié ses résultats financiers du troisième trimestre 2025. La société a réalisé un chiffre d'affaires de 1,39 million de CAD, en hausse par rapport à 1,22 million de CAD au troisième trimestre 2024, avec une perte EBITA ajustée de 99 466 CAD.
Le trimestre a été marqué par une forte performance de leur produit DirectInject-LC™, avec des opportunités doublées par rapport au T3 2024 et une expansion réussie sur les marchés asiatiques. Telescope finalise une plateforme de laboratoire autonome de phase 1 avec Pfizer et a expédié ses premiers échantillons de sulfure de lithium de qualité batterie à des groupes majeurs de l'industrie des batteries, tirant parti de son procédé de production à basse température propriétaire.
L'entreprise maintient des partenariats stratégiques avec Mettler Toledo, Pfizer et Standard Lithium, se positionnant pour une croissance continue dans les innovations analytiques et d'automatisation.
Telescope Innovations (OTCQB:TELIF), ein Entwickler fortschrittlicher Technologien für die Pharma- und Chemieindustrie, berichtete über seine Finanzergebnisse für das dritte Quartal 2025. Das Unternehmen erzielte Umsätze von 1,39 Millionen CAD, gegenüber 1,22 Millionen CAD im dritten Quartal 2024, bei einem bereinigten EBITA-Verlust von 99.466 CAD.
Im Quartal zeigte sich eine starke Leistung ihres DirectInject-LC™-Produkts, mit verdoppelten Chancen im Vergleich zum Q3 2024 und einer erfolgreichen Expansion in asiatische Märkte. Telescope finalisiert eine Phase-1-Selbstfahrende-Labor-Plattform mit Pfizer und hat seine ersten Batteriestufen-Lithiumsulfid-Proben an führende Batterieindustriegremien geliefert, wobei das firmeneigene Niedertemperaturproduktionsverfahren genutzt wird.
Das Unternehmen pflegt strategische Partnerschaften mit Mettler Toledo, Pfizer und Standard Lithium und positioniert sich für weiteres Wachstum in analytischen und Automatisierungsinnovationen.
- Revenue growth to CAD $1.39M, up 13.9% from Q3 2024
- DirectInject-LC sales opportunities more than doubled compared to Q3 2024
- Successful expansion into Asian markets with deployed units in Japan
- Strategic advancement in Self-Driving Lab development with Pfizer
- First shipment of battery-grade Li₂S samples to major battery industry groups
- Expenses increased 33% to CAD $1.89M compared to Q3 2024
- Adjusted EBITA loss widened to CAD $99,466 from CAD $51,413 in Q3 2024
Vancouver, British Columbia--(Newsfile Corp. - July 16, 2025) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company"), a developer of advanced technologies and services for the global pharmaceutical and chemical industries, reports financial results for the fiscal quarter ended May 31, 2025 (Q3). The Company generated revenues of
FINANCIAL HIGHLIGHTS OF THE FISCAL QUARTER ENDED MAY 31, 2025
All values are represented in CAD.
- Revenues of
$1,394,542 (versus$1,224,351 for the comparable quarter in FY 2024) - Expenses of
$1,896,028 (versus$1,424,650 for the comparable quarter in FY 2024) - Adjusted EBITA loss of
$99,466 (versus$51,413 EBITA loss for the comparable quarter in FY 2024)
OPERATIONAL HIGHLIGHTS
- STRONGEST QUARTER YET FOR DIRECTINJECT-LC PRODUCT™. Both sales and order pipelines enjoyed consistent growth this quarter, with the number of opportunities more than doubling compared to Q3, 2024. The recent launch in Asia rapidly converted into sales and deployed units in Japan, alongside a pipeline including multi-system orders in China. We continue working strategically with Mettler Toledo on our global distribution campaign: this quarter we executed 11 application feasibility studies at customer sites across the US, Europe, and Asia; participated in 2 lead-generating InfoDays hosted by Mettler Toledo; and presented at the 2025 IFPAC global conference, one of the largest Process Analytical Technology summits in North America.
- PROGRESS ON SELF-DRIVING LAB DEVELOPMENT WITH PFIZER. Telescope is in the final stage of building and confirmation testing a "Phase 1" Self-Driving Lab (SDL) platform in collaboration with Pfizer. SDLs use artificial intelligence, robotic automation, and advanced process analytical technology to perform chemistry research up to 100x than traditional methods. We are currently discussing the specifications of Phase 2 deliverables to ensure direct alignment of Telescope's technology with industry needs.
- COMMERCIAL ADVANCEMENT OF LITHIUM SULFIDE (Li₂S) PRODUCTION TECHNOLOGY. Telescope shipped its first battery-grade Li₂S samples to major battery industry groups in Asia and North America, marking the initial customer evaluation of its proprietary low-temperature production process. The samples were made with North American feedstocks, including lithium hydroxide monohydrate from Standard Lithium Ltd.'s demonstration plant in southwest Arkansas. Building on this strategic collaboration, Telescope is now part of the inaugural cohort of the first US-based accelerator innovating the battery supply chain: the Arkansas Lithium Technology Accelerator.
"Q3 was marked by strong commercial momentum across our core technologies," said Henry Dubina, Telescope CEO. "Telescope's advanced analytical and automation innovations continue to gain traction with growing DirectInject-LC sales, our leadership in Self-Driving Labs, and the lithium processing technologies we developed with these tools. We're excited to build on our partnerships Mettler Toledo, Pfizer, and Standard Lithium that are positioning us for long-term success."
Readers are encouraged to review the full financial statements and accompanying management discussion and analysis for the fiscal period ended May 31, 2025, both of which are available under the profile for the Company on SEDAR+ (www.sedarplus.ca).
About Telescope
Telescope is a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. The Company builds and deploys new enabling technologies including flexible robotic platforms and artificial intelligence software that improves experimental throughput, efficiency, and data quality. Our aim is to bring modern chemical technology solutions to meet the most serious challenges in health and sustainability.
On behalf of the Board,
Telescope Innovations Corp.
Henry Dubina, Chief Executive Officer
E: hdubina@telescopeinn.com
The CSE has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/259042
FAQ
What were Telescope Innovations (TELIF) Q3 2025 financial results?
How is Telescope's DirectInject-LC product performing in the market?
What progress has Telescope made with Pfizer on the Self-Driving Lab?
What developments has Telescope made in lithium sulfide production?
Who are Telescope's key strategic partners?
